在诱导过程中,较高的乌斯特基努马布度与炎症性肠病的更好的内镜结果有关
Xavier Serra-Ruiz1, Elena Céspedes-Martínez2, Luis Mayorga2
1Crohn's and Colitis Attention Unit, Gastroenterology Department, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, 119, Barcelona 08035, Spain.
Therapeutic advances in gastroenterology
|October 8, 2025
概括
在第8周,更高的乌斯特基努马布 (UST) 水平预测克罗恩氏病和性结肠炎患者的内镜缓解更好. 在第8周UST度为4.5μg/mL是内镜缓解的关键预测指标.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 乌斯特基努马布 (UST) 是一种用于炎症性肠病 (IBD) 的生物疗法.
- 证据表明,在IBD患者中,乌斯特基努马布度和治疗有效性之间存在联系.
- 了解这种关系可以优化患者的治疗结果.
研究的目的:
- 评估在诱导期间的乌斯特基努马布度与克罗恩病 (CD) 和性结肠炎 (UC) 的24周治疗结果之间的关联.
- 确定可预测内镜缓解和反应的乌斯特基努马布度值.
主要方法:
- 对CD和UC患者进行前性观察性研究,开始治疗ustekinumab.
- 在第8周,第16周和第24周测量乌斯特基努马布度.
- 在第24周评估内镜和临床结果.
主要成果:
- 在第24周实现内镜缓解或响应的患者在第8周的乌斯特基努马布水平显着更高.
- 在第8周,乌斯特基努马布度>4.5微克/毫升与更高的内镜缓解率有关.
- 在第8周,乌斯特基努马布度为4.5微克/毫升是预测内镜缓解的最佳预测 (AUC=0.7).
- 疾病持续时间较长增加了停止使用乌斯特基努马布的风险.
结论:
- 在第8周的乌斯特基努马布度与第24周的内镜结果有积极的关联.
- 在第8周,乌斯特基努马布度值为4.5微克/毫升,预测内镜缓解.
- 需要进一步的研究,包括随机试验,以探索基于度监测的优化ustekinumab治疗.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
434
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
434
Inflammatory Bowel Disease IV: Pharmacological Management
517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
517
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490
Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K


